ETNA-VTE Europe: Benefits and risks of venous thromboembolism treatment using edoxaban in the first 3 months.

Agnelli, Giancarlo; Hoffmann, Ulrich; Hainaut, Philippe; Gaine, Sean; Ay, Cihan; Coppens, Michiel; Schindewolf, Marc; Jimenez, David; Brüggenjürgen, Bernd; Levy, Pierre; Laeis, Petra; Fronk, Eva-Maria; Zierhut, Wolfgang; Malzer, Thomas; Manu, Marius Constantin; Reimitz, Paul-Egbert; Bramlage, Peter; Cohen, Alexander T (2020). ETNA-VTE Europe: Benefits and risks of venous thromboembolism treatment using edoxaban in the first 3 months. Thrombosis research, 196, pp. 297-304. Elsevier 10.1016/j.thromres.2020.09.001

[img] Text
AgnelliG_ETNA-VTEEuropeBenefitsAndRisksOfVenous_ThrombRes_2020.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (1MB) | Request a copy

INTRODUCTION

Edoxaban had a positive risk-benefit ratio for the treatment of venous thromboembolism (VTE) compared to conventional therapy with warfarin. The objective of this analysis of the ongoing ETNA-VTE Europe study was to assess the real-world benefits and risks of edoxaban during the first 3 months of treatment, the highest risk period for further VTE events.

METHODS

ETNA-VTE Europe is a prospective, non-interventional, post-authorization study, conducted in eight European countries. Participants had initial or recurrent acute VTE (deep vein thrombosis [DVT] and/or pulmonary embolism [PE]) that occurred ≤2 weeks prior to enrolment and received edoxaban therapy.

RESULTS

The analysis set included 2672 patients (PE ± DVT, n = 1117; DVT only, n = 1555); mean age 62.9 ± 16.0 years, bodyweight 81.9 ± 17.4 kg, estimated glomerular filtration rate 95.4 ± 42.8 mL/min; 46.4% were female. Overall, 66.4% of patients (PE ± DVT, 68.5%; DVT-only, 64.8%) received heparin lead-in treatment for at least 5 days. Most patients (87.7%) received edoxaban at a dose of 60 mg once daily. Event rates at 3 months were: recurrent VTE 0.34% (n = 9), major bleeding 0.97% (n = 26), all-cause mortality 0.79% (n = 21). Rates were numerically higher in the PE ± DVT group compared with the DVT-only group (recurrent VTE, 0.45% (n = 5) versus 0.26% (n = 4); major bleeding, 1.34% (n = 15) versus 0.71% (n = 11); and all-cause mortality 1.16% (n = 13) versus 0.51% (n = 8)).

CONCLUSIONS

The results support the safety and effectiveness of edoxaban in a general VTE population during the most critical time period, the first 3 months. The outcomes of this study extend the principal efficacy and safety data on edoxaban into the routine clinical practice setting.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Cardiovascular Disorders (DHGE) > Clinic of Angiology

UniBE Contributor:

Schindewolf, Marc

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0049-3848

Publisher:

Elsevier

Language:

English

Submitter:

Claudine Strametz

Date Deposited:

25 Nov 2020 10:15

Last Modified:

25 Nov 2020 10:15

Publisher DOI:

10.1016/j.thromres.2020.09.001

PubMed ID:

32950897

Uncontrolled Keywords:

Clinical outcomes Deep vein thrombosis Edoxaban Pulmonary embolism Registry Routine clinical practice Venous thromboembolism

BORIS DOI:

10.7892/boris.147548

URI:

https://boris.unibe.ch/id/eprint/147548

Actions (login required)

Edit item Edit item
Provide Feedback